Background: Early detection of ocular manifestations associated with hydroxychloroquine toxicity is imperative in the medical field. Due to the potential for irreversible ocular alterations that can ultimately result in vision loss, it is crucial to acknowledge that these changes may already be present by the time symptoms become apparent. Methods: During the two-year period, a prospective study was conducted within a hospital setting. The research encompassed a cohort of 50 individuals who were clinically diagnosed with either rheumatoid arthritis or systemic lupus erythematosus. These cases were selected from the departments of medicine and dermatology and were on the verge of initiating hydroxychloroquine (HCQ) treatment. Over a span of six months, each patient underwent a minimum of two subsequent visits, with a time gap of three months between each visit. A comprehensive ophthalmological evaluation was conducted, including optical coherence tomography (OCT) and perimetry, for each individual case. Results: The research findings indicated that the occurrence of ocular toxicities associated with hydroxychloroquine administration at low to regular doses (≤6.5mg/kg body weight) for a brief period (≤1 year) was observed to be 0%. Conclusion: Hydroxychloroquine is a pharmaceutical agent that exhibits a high degree of safety when administered within the recommended therapeutic range of low to regular doses (not exceeding 6.5 milligrammes per kilogramme of body weight). Furthermore, it is advisable to limit the duration of treatment to a period not exceeding one year.